Baylor Scott & White Health: First-of-Its-Kind Breast Cancer Research Study Explores the Impact of Weight Loss Drugs on Recurrence
December 12, 2024
December 12, 2024
DALLAS, Texas, Dec. 12 (TNSres) -- Baylor Scott and White Health issued the following news release:
* * *
TRIM-EBC/* clinical trial studying whether weight loss from Zepbound(R) (tirzepatide) can lower the risk of breast cancer recurrence by reducing or clearing circulating tumor DNA (ctDNA)
* * *
A breast cancer research study now open at Baylor University Medical Center in Dallas is believed to be the first of its kind to explore the ability . . .
* * *
TRIM-EBC/* clinical trial studying whether weight loss from Zepbound(R) (tirzepatide) can lower the risk of breast cancer recurrence by reducing or clearing circulating tumor DNA (ctDNA)
* * *
A breast cancer research study now open at Baylor University Medical Center in Dallas is believed to be the first of its kind to explore the ability . . .